Posttransplant Antidonor Lymphocytotoxic Antibody Production in Relation to Graft Outcome

Martin, Susan; Dyer, Philip A.; Mallick, N. P.; Gokal, Ram; Harris, Rodney; Johnson, Robert W.

doi:10.1097/00007890-198707000-00012

Cited by 97 publications

(35 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Specificity analysis demonstrated that most posttransplantation anti-HLA antibodies are donor reactive and confirmed previous assertions for associations of both class I DSA [14,15,17,35,36] and class II DSA [14,17,37,38] with rejections and generally worse graft outcomes. Immunologic complications occurred in our kidney recipients with CREG or non-donor-specific antibodies alone, which is consistent with other observations on alloantibody specificity pattern and graft outcome [19,20].…”

Section: Discussionsupporting

confidence: 83%

Clinical Relevance of Anti-HLA Antibodies Detected by Flow-Cytometry Bead-Based Assays—Single-Center Experience

et al. 2006

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 83%

Clinical Relevance of Anti-HLA Antibodies Detected by Flow-Cytometry Bead-Based Assays—Single-Center Experience

et al. 2006

View full text Add to dashboard Cite

“…The length of hospital stay after transplantation was also longer in our PRA positive patients than the PRA negative patients. High incidence of rejection in PRA positive patients and the need for antirejection and supportive treatments may cause the long hospital stay in these patients (22). Deka et al (23) also reported a long hospital stay in PRA positive patients which is in conformity with our results.…”

Section: Discussionsupporting

confidence: 92%

Long-Term Effects of Antibodies against Human Leukocyte Antigens Detected by Flow Cytometry in the First Year after Renal Transplantation

Ayna¹,

Çalışkan²,

Çiftçi³

et al. 2013

Balkan Med J

View full text Add to dashboard Cite

Objective: In this study, we aimed to investigate the incidence, dynamics and profiles of human leukocyte antigen (HLA)-directed antibodies developed after transplantation and their impact on graft rejection and outcome in kidney recipients.Study Design: Prospective follow-up study.Material and Methods: A total of 56 kidney recipients were monitored at 1 st , 6 th and 12 th months for the development of anti-HLA antibodies using bead based flow-cytometry assays (Flow PRA tests).Results: In 21 (37.5%) patients, panel reactive antibodies (PRA) was positive after transplantation, however, in 35 (62.5%) patients PRA was found negative. Twelve (57.1%) patients with post-transplantation HLA-reactive antibodies [PRA (+)] and 8 (22.9%) patients with no detectable alloantibodies [PRA (-)] were developed allograft rejection (p=0.010). In the PRA positive patient group the rates of early period infection and delayed graft function (DGF) were higher than the PRA negative patient group. Serum creatinine levels of PRA positive group at 6. and 12. months after transplantation were significantly higher than the PRA negative group (p=0.015 and p=0.048, respectively). The rejection rates of patients who had class I and II HLA antibodies were significantly higher than the patients who had either class I or II HLA antibodies (p=0.011). Acute rejection rates were significantly higher in patients who had class I and II HLA antibodies at the first month (p=0.007). Conclusion:Higher occurrence of rejection episodes in PRA positive group may show the importance of anti-HLA antibody monitoring using Flow-PRA after renal transplantation as a prognostic marker in terms of graft survival.

show abstract

“…An earlier study by Martin et al (5) showed that most de novo anti-HLA antibodies were anti-HLA class I (50% class I alone and 36% both classes I and II). In the early 1990s, Halloran et al (8) studied class I anti-HLA antibodies by the CDC method in 64 patients within the first 3 mo after transplantation.…”

Section: Type Of Antibody and Its Effect On Allograft Outcomementioning

confidence: 98%

Sensitization after Kidney Transplantation

Akalin¹,

Pascual²

2006

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

Kidney transplant recipients may develop de novo anti-HLA and non-HLA antibodies after transplantation. Although these antibodies may be donor-specific or non-donor-specific, their presence may increase the risk for acute and chronic rejection, thereby decreasing allograft survival. The introduction of more sensitive and specific methods to detect anti-HLA antibodies, such as Flow Specific Beads and FlowPRA, both before and after transplantation, will help to define immunologically high-risk kidney transplant recipients. Thus, posttransplantation monitoring of anti-HLA antibody production will allow the identification of kidney transplant recipients who might be at increased risk for late allograft failure. Moreover, knowledge of alloantibody status after transplantation may help to guide the appropriate use of immunomodulatory agents to downregulate anti-HLA antibody production.

show abstract

Posttransplant Antidonor Lymphocytotoxic Antibody Production in Relation to Graft Outcome

Cited by 97 publications

References 0 publications

Clinical Relevance of Anti-HLA Antibodies Detected by Flow-Cytometry Bead-Based Assays—Single-Center Experience

Clinical Relevance of Anti-HLA Antibodies Detected by Flow-Cytometry Bead-Based Assays—Single-Center Experience

Long-Term Effects of Antibodies against Human Leukocyte Antigens Detected by Flow Cytometry in the First Year after Renal Transplantation

Sensitization after Kidney Transplantation

Contact Info

Product

Resources

About